Troy J. Plumb,1
Lisa A. Robinson,1
Robert Spurney,1
David Pisetsky,2
Beverly H. Koller,3 and
Thomas M. Coffman1*
Division of Nephrology, Duke University, and Durham VA Medical Centers, Durham, North Carolina,1 Division of Immunology, Duke University, and Durham VA Medical Centers, Durham, North Carolina,2 Department of Medicine, the University of North Carolina, Chapel Hill, North Carolina3
Received 17 March 2005/ Returned for modification 13 April 2005/ Accepted 4 May 2005
Lipopolysaccharide (LPS) causes apoptotic deletion of CD4+ CD8+ thymocytes, a phenomenon that has been linked to immune dysfunction and poor survival during sepsis. Given the abundance of thromboxane-prostanoid (TP) receptors in CD4+ CD8+ thymocytes and in vitro evidence that thromboxane A2 (TXA2) causes apoptosis of these cells, we tested whether enhanced generation of TXA2 plays a role in LPS-induced thymocyte apoptosis. Mice injected with 50 µg of LPS intraperitoneally displayed a marked increase in generation of TXA2 and prostaglandin E2 in the thymus as well as apoptotic deletion of CD4+ CD8+ thymocytes. Administration of indomethacin or rofecoxib inhibited prostanoid synthesis but did not affect thymocyte death. In contrast, thymocyte apoptosis in response to LPS was significantly attenuated in TP-deficient mice. These studies indicate that TXA2 mediates a portion of apoptotic thymocyte death caused by LPS. The absence of an effect of global inhibition of prostanoid synthesis suggests a complex role for prostanoids in this model.
Present address: Hospital Universitario Professor Edgard Santos, Laboratorio de Imunologia, 5o andar, Rua João das Botas s/n, Canela, Salvador-BA, 40110-160, Brazil.
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. | Infect. Immun. |
|---|---|---|
| J. Clin. Microbiol. | J. Virol. | ALL ASM JOURNALS |